OpenNashEarnings

Pharmaceuticals · NYSE: NVS

Novartis earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 3 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Novartis won FDA approval for Rhapsido in a second disease and posted positive remibrutinib multiple sclerosis data, lifting Rhapsido's peak sales target to USD 4bn+.

Priority brands including Kisqali, Kesimpta, Scemblix and Leqvio grew fast enough to more than offset generic erosion, mainly Entresto in the US. Rhapsido, the new oral treatment for chronic spontaneous urticaria (CSU), has treated over 15,000 patients in the US and won FDA approval in symptomatic dermographism. Pluvicto gained US and China approval in earlier-stage prostate cancer, and remibrutinib succeeded in two Phase III multiple sclerosis trials.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

20-F filings